Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR）
ENDEAVOR
1 other identifier
observational
2,000
1 country
1
Brief Summary
In this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2024
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 14, 2023
CompletedFirst Posted
Study publicly available on registry
July 28, 2023
CompletedStudy Start
First participant enrolled
May 9, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2028
July 12, 2024
March 1, 2024
4.6 years
February 14, 2023
July 10, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in the incidence of MACCE
MACCE is major adverse cardio-cerebrovascular events, including myocardial infarction, stroke, vessel revascularization and all-cause death. The MACCE will be assessed from the medical records.
1, 3, 6 months and 1, 2, 3, 5 years after enrollment.
Secondary Outcomes (6)
Incidence of adverse thrombus complications
5 years after the enrollment.
Change in the incidence of infection recurrence
1, 3, 6 months and 1, 2, 3, 5 years after enrollment.
Change in the incidence of myocardial infarction
1, 3, 6 months and 1, 2, 3, 5 years after enrollment.
Change in the incidence of stroke
1, 3, 6 months and 1, 2, 3, 5 years after enrollment.
Change in the incidence of vessel revascularization
1, 3, 6 months and 1, 2, 3, 5 years after enrollment.
- +1 more secondary outcomes
Study Arms (1)
Infective endocarditis group
Patients diagnosed with infective endocarditis.
Interventions
Observational; No Interventions were given.
Eligibility Criteria
Patients with clinically confirmed infective endocarditis
You may qualify if:
- Patients with clinically confirmed infective endocarditis
You may not qualify if:
- Patients refuse to sign informed consent form
- Patients who combined with serious systemic diseases, cannot tolerate the acquisition of biological samples
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- First Affiliated Hospital Xi'an Jiaotong Universitylead
- 521 Hospital of NORINCO Groupcollaborator
- Shaanxi Provincial People's Hospitalcollaborator
- Xiangyang Central Hospitalcollaborator
- Henan Provincial People's Hospitalcollaborator
Study Sites (1)
First Affiliated Hospital of Xian Jiantong University
Xi'an, Shaanxi, 710061, China
Biospecimen
Blood, feces, urine, valvular, superfluous organisms, adipose tissue and pericardial effusion.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yang Yan
First Affiliated Hospital Xi'an Jiaotong University
- PRINCIPAL INVESTIGATOR
Guoliang Li
First Affiliated Hospital Xi'an Jiaotong University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 14, 2023
First Posted
July 28, 2023
Study Start
May 9, 2024
Primary Completion (Estimated)
December 31, 2028
Study Completion (Estimated)
December 31, 2028
Last Updated
July 12, 2024
Record last verified: 2024-03